AtaiBeckley Inc. (NASDAQ:ATAI) shares are trending on Thursday.
Lilly Eyes Acquisition At A Premium
Shares of the New York-based psychedelic drugmaker jumped 64.70% to $8.83 after the bell. On Wednesday, Reuters, citing Bloomberg News, reported Eli Lilly and Co. (NYSE:LLY) is in talks to acquire AtaiBeckley, with a deal possibly announced as soon as this week.
According to the report, Lilly is negotiating the acquisition at a premium.
AtaiBeckley and Eli Lilly did not immediately respond to Benzinga‘s request for comment.
AtaiBeckley is developing BPL-003, a nasal spray formulation of 5-MeO-DMT designed to treat depression that has not responded to other treatments. In earlier trial results, the company reported that 66.7% of patients showed an antidepressant response by Day 2, and 83% of those patients continued to maintain that response through Week 12.
Trading Metrics, Technical Analysis
According to Benzinga Pro data, AtaiBeckley closed the regular session up 5.47% at $5.36. Lilly shares were up 0.35% at $1,156.63.
| Company | Market Cap | 52-Week High | 52-Week Low | Shares Outstanding |
|---|---|---|---|---|
| AtaiBeckley | $1.97 billion | $6.73 | $2.59 | 368.17 million |
| Eli Lilly | $1.09 trillion | $1,249.45 | $623.78 | 941.74 million |
AtaiBeckley is currently trading at about 67% of its 52-week range.
Over the past 12 months, ATAI has gained 98.52%.
ATAI’s long-term trend and strong market position indicate the potential for further gains.
With a strong Momentum in the 95th percentile, Benzinga’s Edge Stock Rankings indicate that ATAI has a positive price trend across all time frames.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: prassarp on Shutterstock.com